Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer
Summary
The purpose of this phase Ib trial is to evaluate the side effects and best dose of guadecitabine and how well it works when given together with durvalumab in treating patients with liver, pancreatic, bile duct, or gallbladder cancer that has spread to other places in the body.
General Information
NCT#: NCT03257761
Study ID: 0S-16-18
Trial Phase: Phase I
Trial Sponsor: National Cancer Institute (NCI), University of Southern California (USC)
Therapies Used in This Trial: Durvalumab, Guadecitabine